Kailera Therapeutics, Inc. KLRA
—
11.22
(0.76)
(6.34%)
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow KLRA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+2 more TTM periods Free account |
— | — | — | 0.00% | |
| — | — | 0.00% | (39.14%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (79.67%) | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (27.98%) | |
Free Cash Flow per Share |
0.00 | 0.00 | (10,784.81) | (2.86) | |
Free Cash Flow |
— | (164.64) | (232.95) | (292.28) | |
Piotroski F-Score |
— | — | — | 0.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | (13.93%) | (21.58%) | (14.36%) | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 1.23 | |
Depreciation/Fixed assets |
— | 0.22 | 0.29 | 0.33 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | (10,784.81) | (2.86) | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
— | — | — | 0.00% |
Columns are period end dates